Chester County News and Community Website
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced the recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of …
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain Read More
MALVERN, PA — Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) recenlty accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic …
FDA Accepts Venatorx Pharmaceuticals’ New Drug Application for Cefepime-Taniborbactam Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that it recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New …
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced on Monday the completion of the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration …
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, announced it has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and …
Madrigal Pharmaceuticals Initiates NDA Rolling Submission for Breakthrough Liver Fibrosis Treatment Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN), a pharmaceutical company, this week announced the U.S. Food and Drug Administration (FDA) accepted for review its supplemental new drug application (sNDA) requesting approval …
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the recent presentation on Friday, March 10, 2023, of a net treatment benefit analysis of Phase 3 ROMAN results at the …
Groundbreaking SOM Analysis by Galera Presented at ECHNO Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently reported the minutes of a Type B meeting with the U.S. Food and Drug Administration’s Division of Psychiatry Products held on January 11, …
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that this week it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) …
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 Read More